Health

Start Thinking ‘Cure’; One More Hug; Mortgages and Breast Cancer Survival

Start thinking “cure” in cancer, Janssen’s head of global oncology therapeutics advised pharma executives during a virtual meeting. (Fierce Pharma)

Patients with early-stage, HER2-negative, BRCA-mutant breast cancer should be offered a year of adjuvant olaparib (Lynparza) following neoadjuvant therapy and local treatment, according to a rapid guideline update from the American Society of Clinical Oncology.

“Give me one more hug.” When words fail during an oncologist’s last meeting with a dying patient. (JCO: Art of Oncology)

A phase I trial of the IDH1/2 inhibitor vorasidenib in recurrent non-enhancing glioma showed a favorable safety profile, an objective response rate of 18%, and a median progression-free survival of 3.1 years, Servier announced.

A survey by the American Academy of Dermatology showed that only a third of Americans are concerned about developing skin cancer, even though 70% may have one or more risk factors.

Results of a phase I/II trial of the RET inhibitor pralsetinib (Gavreto) showed response rates of 60% to 90% in RET fusion-positive non-small cell lung cancer and RET fusion-positive or RET-mutant thyroid cancer. (University of Texas MD Anderson Cancer Center)

Uncovering more clues to the association between high-fat diet and colon cancer. (Cell Reports, Arizona State University)

A personalized liquid biopsy showed potential for predicting outcomes with immunotherapy for bladder cancer. (Nature)

Legislation introduced in both houses of Congress would ban a class of potentially cancer-causing chemicals known as PFAS from a variety of widely used cosmetics. (CNN)

Blueprint Medicines announced FDA approval of avapritinib (Ayvakit) for adults with advanced systemic mastocytosis. Read MedPage Today‘s coverage of a study that supported the approval.

Does mortgage lending bias affect breast cancer survival? (Journal of Clinical Oncology)

  • Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.